C. Sarrecchia

发表

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

P. Aiello, C. Sarrecchia, A. Cappelli, 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Two-year surveillance on fluconazole susceptibility of Candida spp isolates in a general and university hospital in Rome.

M. Andreoni, F. Falco, G. Bontempo, 2001, Diagnostic microbiology and infectious disease.

Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.

B. Berkhout, F. Ceccherini‐Silberstein, M. Andreoni, 2013, The Journal of infection.

Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy.

M. Andreoni, C. Perno, A. Bertoli, 2012, The Journal of infection.

Granulocyte–macrophage colony‐stimulating factor regulates cytokine production in cultured macrophages through CD14‐dependent and ‐independent mechanisms

A. Bergamini, F. Bolacchi, G. Rocchi, 2000, Immunology.

Long-Term Intramuscular Teicoplanin Treatment of Chronic Osteomyelitis Due to Oxacillin-Resistant Staphylococcus aureus in Outpatients

M. Andreoni, I. Uccella, C. Sarrecchia, 2000, Journal of chemotherapy.

Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.

C. Perno, A. Bertoli, A. Spanò, 2011, Antiviral research.

Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Y. Louzoun, M. Andreoni, C. Perno, 2015, Hepatology.

HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors

Stefano Alcaro, Anna Artese, Lucia Parrotta, 2012, PloS one.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

Domenico Di Carlo, F. Ceccherini‐Silberstein, H. Fleury, 2017, Oncotarget.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

B. Berkhout, H. Fleury, M. Andreoni, 2015, The Journal of infection.

Snapshot on drug‐resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

C. Perno, M. Andreoni, M. Angelico, 2013, Journal of medical virology.

High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance

M. Andreoni, C. Perno, V. Svicher, 2018, PloS one.

Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2012, Antiviral research.

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.

A. Gasbarrini, F. Ceccherini‐Silberstein, V. Vullo, 2016, The Journal of antimicrobial chemotherapy.

HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression

Y. Louzoun, C. Perno, M. Andreoni, 2014 .

Multidrug resistance after lamivudine therapy for chronic hepatitis B.

M. Andreoni, A. Volpi, C. Sarrecchia, 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance

C. Perno, M. Andreoni, A. Bertoli, 2011, Infection.

Aciclovir, herpes viruses and HIV: a never-ending story

A. Volpi, C. Sarrecchia, P. Sordillo, 2009, Expert review of anti-infective therapy.

Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.

F. Ceccherini‐Silberstein, M. Andreoni, S. Babudieri, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Antibiotic Susceptibility of Lactobacilli Isolated from the Cervix of Healthy Women

M. Andreoni, C. Sarrecchia, E. Valli, 2002 .

Microbiological Approach in Diagnosing Native and Heart Valves Prosthesis Infections

C. Fontana, C. Favalli, C. Sarrecchia, 2017 .

Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype

M. Andreoni, F. Spandonaro, C. Sarrecchia, 2016, Medicine.

Detection of high levels of Survivin–immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis

G. Rasi, P. Pontisso, S. Bernardini, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Atorvastatin-Associated Gynecomastia

G. Famularo, C. Sarrecchia, 2021, The Annals of pharmacotherapy.

Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.

F. Baldanti, F. Ceccherini‐Silberstein, E. Teti, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Aciclovir, herpes viruses and HIV: a never-ending story

A. Volpi, C. Sarrecchia, P. Sordillo, 2009, Expert review of anti-infective therapy.